Abstract

Competing Risk Model to Determine the Prognostic Factors and Treatment Strategies for Adult Patients with Malignant Meningioma: a SEER Population-Based Study

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Atypical and Malignant Meningioma: Outcome and Prognostic Factors in 119 Irradiated Patients: A Multicentre, Retrospective Study of the Rare Cancer Network
D Pasquier ... T Tzuk-Shina
International Journal of Radiation Oncology, Biology, Physics | VOL. 69
D Pasquier, et. al.D Pasquier ... T Tzuk-Shina
27 Sep 2007
Competing Risk Model to Determine the Prognostic Factors and Treatment Strategies for Adult Patients with Malignant Meningioma: a SEER Population-Based Study
...
Zenodo (CERN European Organization for Nuclear Research) | VOL. -
, et. al. ...
08 Jan 2023
Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas.
Daniel Kim ... Jay S Loeffler
Journal of Neurosurgery: Spine | VOL. 128
Daniel Kim, et. al.Daniel Kim ... Jay S Loeffler
16 Jun 2017
Author response for "Competitive Risk Model Nomogram to Predict Prognosis in Patients Aged Over 65 Years with nonmetastatic Cervical Cancer: A SEER Population-Based Study"
Shengyuan Jiao ... Fei Da
-
Shengyuan Jiao, et. al. Shengyuan Jiao ... Fei Da
29 Nov 2022
View more papers

More From: Zenodo (CERN European Organization for Nuclear Research)

Paper Title
Journal
Date
Author
Differences in the genomic diversity, structure and inbreeding patterns in wild and managed populations of Agave potatorum used in the production of Tobalá mezcal in Southern México.
Zenodo (CERN European Organization for Nuclear Research) | VOL. -
10 Jul 2024
Data for peer review
...
Zenodo (CERN European Organization for Nuclear Research) | VOL. -
, et. al. ...
30 Jun 2024
Therapy-induced APOBEC3A drives evolution of resistance to targeted therapies in non-small cell lung cancer
...
Zenodo (CERN European Organization for Nuclear Research) | VOL. -
, et. al. ...
17 May 2024
How long should my personal statement be dermatology residency?
Zenodo (CERN European Organization for Nuclear Research) | VOL. -
10 May 2024
View more papers